Design and baseline characteristics of the Xarelto Post‐Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS)

BACKGROUND: The phase III Japanese Rivaroxaban Once‐Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (J‐ROCKET AF) showed that the rivaroxaban group had a lower event rate of intracranial bleeding than the wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogawa, Satoshi, Minematsu, Kazuo, Ikeda, Takanori, Kitazono, Takanari, Nakagawara, Jyoji, Miyamoto, Susumu, Murakawa, Yuji, Ohashi, Yohei, Takeichi, Makiko, Okayama, Yutaka, Yamanaka, Satoshi, Inuyama, Lyo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891422/
https://www.ncbi.nlm.nih.gov/pubmed/29657592
http://dx.doi.org/10.1002/joa3.12034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891422/
https://www.ncbi.nlm.nih.gov/pubmed/29657592
http://dx.doi.org/10.1002/joa3.12034

Ejemplares similares